Published in

American Society of Hematology, Blood, 2024

DOI: 10.1182/blood.2023021906

Links

Tools

Export citation

Search in Google Scholar

Non-coding mutations drive persistence of a founder pre-leukemic clone which initiates late relapse in T-ALL

Distributing this paper is prohibited by the publisher
Distributing this paper is prohibited by the publisher

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

T-ALL relapse usually occurs early but can occur much later, which has been suggested to represent a de novo leukemia. However, we conclusively demonstrate late relapse can evolve from a pre-leukemic subclone harbouring a non-coding mutation that evades initial chemotherapy.